BR9907735A - Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion - Google Patents

Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Info

Publication number
BR9907735A
BR9907735A BR9907735-3A BR9907735A BR9907735A BR 9907735 A BR9907735 A BR 9907735A BR 9907735 A BR9907735 A BR 9907735A BR 9907735 A BR9907735 A BR 9907735A
Authority
BR
Brazil
Prior art keywords
inhibitors
bone resorption
formula
cell adhesion
compounds
Prior art date
Application number
BR9907735-3A
Other languages
Portuguese (pt)
Inventor
Anuschirvan Peyman
David Will
Jochen Knolle
Karl-Heinz Scheunemann
Denis Carniato
Jean-Francois Gourvest
Thomas R Gadek
Robert Mcdowell
Sarah Catherine Bodary
Robert Andrew Cuthbertson
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of BR9907735A publication Critical patent/BR9907735A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE SULFONAMIDA COMO INIBIDORES DE REABSORçãO óSSEA E COMO INIBIDORES DA ADERêNCIA CELULAR"<D>. A presente invenção refere-se a derivados de sulfonamida de fórmula (I), em que R^ 1^ , R^ 2^, R^ 4^, R^ 5^ e R^ 6^ têm os significados indicados nas reivindicações, seus sais fisiologicamente toleráveis e seus pró-medicamentos. Os compostos da fórmula (I) são compostos ativos farmacêuticos valiosos. Eles são antagonistas receptores de vitronectina e inibidores da aderência celular e inibem a reabsorção óssea mediante os osteoclastos. Eles são adequados, por exemplo, para a terapia e profilaxia de doenças que são causadas pelo menos parcialmente por um grau indesejado de reabsorção óssea, por exemplo, da osteoporose. A invenção além disso refere-se a processos para a preparação de compostos da fórmula (I), seu uso, em particular como ingredientes ativos farmacêuticos, e preparação farmacêuticas compreendendo-os.Invention Patent: <B> "SULPHONAMIDE DERIVATIVES AS BONE REABSORPTION INHIBITORS AND AS CELL ADHERENCE INHIBITORS" <D>. The present invention relates to sulfonamide derivatives of formula (I), wherein R ^ 1 ^, R ^ 2 ^, R ^ 4 ^, R ^ 5 ^ and R ^ 6 ^ have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and inhibit bone resorption through osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases that are caused at least partially by an unwanted degree of bone resorption, for example, from osteoporosis. The invention further relates to processes for the preparation of compounds of formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them.

BR9907735-3A 1998-01-23 1999-01-16 Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion BR9907735A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
PCT/EP1999/000242 WO1999037621A1 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
BR9907735A true BR9907735A (en) 2000-10-17

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907735-3A BR9907735A (en) 1998-01-23 1999-01-16 Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Country Status (25)

Country Link
EP (1) EP1049677A1 (en)
JP (1) JP2002501054A (en)
KR (1) KR20010034319A (en)
CN (1) CN1177832C (en)
AP (1) AP1269A (en)
AR (1) AR014456A1 (en)
AU (1) AU752882B2 (en)
BG (1) BG104630A (en)
BR (1) BR9907735A (en)
CA (1) CA2318221A1 (en)
EA (1) EA003102B1 (en)
HR (1) HRP20000493A2 (en)
HU (1) HUP0100520A3 (en)
ID (1) ID26219A (en)
IL (1) IL137423A0 (en)
NO (1) NO318795B1 (en)
NZ (1) NZ505613A (en)
PL (1) PL341871A1 (en)
SK (1) SK10632000A3 (en)
TR (1) TR200002160T2 (en)
TW (1) TWI247742B (en)
UA (1) UA63990C2 (en)
WO (1) WO1999037621A1 (en)
YU (1) YU47200A (en)
ZA (1) ZA99476B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521450A (en) * 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1070707A1 (en) * 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
FR2847254B1 (en) 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
BRPI0509150B8 (en) * 2004-03-24 2021-05-25 Jerini Ag compounds for the inhibition of angiogenesis and the use of these
FR2870541B1 (en) * 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (en) * 2004-07-27 2006-11-17 Aventis Pharma Sa NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741796A (en) * 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (en) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス Bone formation promoter

Also Published As

Publication number Publication date
NO20003765L (en) 2000-09-25
NZ505613A (en) 2002-11-26
EP1049677A1 (en) 2000-11-08
AU2518199A (en) 1999-08-09
EA003102B1 (en) 2002-12-26
IL137423A0 (en) 2001-07-24
BG104630A (en) 2001-04-30
TWI247742B (en) 2006-01-21
HUP0100520A3 (en) 2002-11-28
PL341871A1 (en) 2001-05-07
AU752882B2 (en) 2002-10-03
CN1293662A (en) 2001-05-02
HRP20000493A2 (en) 2001-06-30
ID26219A (en) 2000-12-07
SK10632000A3 (en) 2001-02-12
NO20003765D0 (en) 2000-07-21
AP1269A (en) 2004-04-03
ZA99476B (en) 1999-08-05
EA200000785A1 (en) 2001-02-26
JP2002501054A (en) 2002-01-15
YU47200A (en) 2002-11-15
UA63990C2 (en) 2004-02-16
WO1999037621A1 (en) 1999-07-29
NO318795B1 (en) 2005-05-09
CN1177832C (en) 2004-12-01
KR20010034319A (en) 2001-04-25
AP2000001863A0 (en) 2000-09-30
AR014456A1 (en) 2001-02-28
CA2318221A1 (en) 1999-07-29
HUP0100520A1 (en) 2001-07-30
TR200002160T2 (en) 2001-07-23

Similar Documents

Publication Publication Date Title
BR9907735A (en) Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
BR9814308A (en) Acylguanidine derivatives as bone resorption inhibitors and as vitronectin receptor antagonists
BR9706387A (en) Substituted purine derivatives, processes for their preparation, their use and compositions containing the same
BR0213562A (en) Benzimidazoles and analogs and their use as protein kinase inhibitors
BR0111263A (en) 2-Aminocarbonyl-9h-purine derivatives
BR0116237A (en) Compounds, pharmaceutical compositions, use of any one or more compounds, and process for the manufacture of pharmaceutical compositions
BR0307575A (en) Sulphonyl derivatives as histone deacetylase inhibitors
BR0110767A (en) Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
BR0214757A (en) Pharmaceutical Formulations of Platinum Derivatives
BR0214243A (en) Sulfonamide derivative Process for the preparation of a sulfonamide derivative and its physiologically acceptable salts, pharmaceutical composition and use of a sulfonamide derivative
BR0207715A (en) Compounds, pharmaceutical compositions, and use of one or more compounds
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
BR9916367A (en) New biphenyl compounds and debiphenyl analogs as integrin antagonists
BR9907270A (en) Compound, pharmaceutical composition, use of a compound, and, processes for the treatment or prophylaxis of inflammatory diseases, for example, asthma or copd, and for the preparation of a compound
CA2371789A1 (en) Novel guanidine derivatives as inhibitors of cell adhesion
BR0317459A (en) New piperidine derivatives as chemokine ccr5 receptor modulators
BR0214141A (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
BR0009561A (en) 1,4-didro indeno [1,2-c] pyrazoles substituted as tyrosine kinase inhibitors
BR0012129A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
BRPI0410195A (en) chemical compounds
BR0012050A (en) Purine derivatives substituted as inhibitors of cell adhesion
BR0109617A (en) Pharmaceutical composition, oligosaccharide, process for preparing oligosaccharides, and use of oligosaccharides
BRPI0407456A (en) 2- (Sulfo-phenyl) -aminothiazole antiproliferative derivatives and pharmaceutical compositions, and methods for their use
BR0314709A (en) Pyrazole Derivatives
BR0009285A (en) Avermectin derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1946 DE 22/04/2008.